Exploration of New Contrasts, Targets, and MR Imaging and Spectroscopy Techniques for Neuromuscular Disease


Gustav J Strijkers, Ericky C,A Araujo, Noura Azzabou, David Bendahan, Andrew Blamire, Jedrek Burakiewicz, Pierre G. Carlier, Bruce Damon, Xeni Deligianni, Martijn Froeling, Arend Heerschap, Kieren G. Hollingsworth, Melissa T. Hooijmans, Dimitrios C. Karampinos, George Loudos, Guillaume Madelin, Benjamin Marty, Armin M. Nagel, Aart J. Nederveen, Jules L. Nelissen, Francesco Santini, Olivier Scheidegger, Fritz Schick, Christopher Sinclair, Ralph Sinkus, Paulo L. de Sousa, Volker Straub, Glenn Walter, Hermien E. Kan.

A Workshop Report of Working Group 3 of the Biomedicine and Molecular Biosciences COST Action BM1304 MYO-MRI

Neuromuscular diseases are characterized by progressive muscle degeneration and muscle weakness resulting in functional disabilities. While each of these diseases is individually rare, they are common as a group, and a large majority lacks effective treatment with fully market approved drugs. Magnetic resonance imaging and spectroscopy techniques (MRI and MRS) are showing increasing promise as an outcome measure in clinical trials for these diseases. In 2013, the European Union funded the COST (co-operation in science and technology) action BM1304 called MYO-MRI (www.myo-mri.eu), with the overall aim to advance novel MRI and MRS techniques for both diagnosis and quantitative monitoring of neuromuscular diseases through sharing of expertise and data, joint development of protocols, opportunities for young researchers and creation of an online atlas of muscle MRI and MRS. In this report, the topics that were discussed in the framework of working group 3, which had the objective to: Explore new contrasts, new targets and new imaging techniques for NMD are described. The report is written by the scientists who attended the meetings and presented their data. An overview is given on the different contrasts that MRI can generate and their application, clinical needs and desired readouts, and emerging methods.

Published: 30 January 2019
Journal: Journal of Neuromuscular Disorders, volume 6, issue 1, pages 1-30

Link: doi.org/10.3233/JND-180333

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern